The interpretation of urothelial carcinoma at the 2023 ASCO-GU
10.3760/cma.j.cn112330-20230327-00003
- VernacularTitle:2023 ASCO-GU尿路上皮癌精粹解读
- Author:
Yige BAO
1
;
Sujun HAN
;
Hai HUANG
Author Information
1. 四川大学华西医院泌尿外科，成都 610041
- Keywords:
Urothelial carcinoma;
Non-muscle invasive bladder cancer;
Muscle-invasive bladder cancer;
Oncoimmunotherapy;
American Society of Clinical Oncology-genitou
- From:
Chinese Journal of Urology
2023;44(4):251-254
- CountryChina
- Language:Chinese
-
Abstract:
The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) reported several advancements in the field of urothelial carcinoma. Multiple new treatment options for non-muscle invasive bladder cancer (NMIBC) were introduced, providing more choices for bladder preservation in BCG-resistant/failed NMIBC cases. In muscle invasive bladder cancer (MIBC) perioperative treatment, the updated 3-year follow-up data from the CheckMate 274 study demonstrated a clear advantage in disease-free survival for the nivolumab monotherapy adjuvant treatment group. For metastatic urothelial carcinoma (mUC), the final overall survival (OS) report from the IMvigor130 study was published, prompting further considerations for future first-line treatment options in mUC. Additionally, the conference highlighted research progress in upper tract urothelial carcinoma (UTUC).
